The effects of Tripterygium wilfordii Hook F on renal outcomes in type 2 diabetic kidney disease patients with severe proteinuria: a single-center cohort study

References

• Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2020;75(1 Suppl 1):1–8. doi: 10.1053/j.ajkd.2019.09.003.
   PubMedGoogle Scholar
• Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20(8):1813–1821. doi: 10.1681/ASN.2008121270.
   PubMed Web of Science ®Google Scholar
• Coresh J, Heerspink HJL, Sang Y, et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 2019;7(2):115–127. doi: 10.1016/S2213-8587(18)30313-9.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi: 10.1056/NEJMoa1811744.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311–322. doi: 10.1056/NEJMoa1603827.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23):2219–2229. doi: 10.1056/NEJMoa2025845.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436–1446. doi: 10.1056/NEJMoa2024816.
   PubMed Web of Science ®Google Scholar
• de Boer IH, Khunti K, Sadusky T, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075–3090. doi: 10.2337/dci22-0027.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Nakamura T, Sato E, et al. Therapeutic potential of tofogliflozin on nephrotic syndrome secondary to diabetic nephropathy. J Cardiol Cases. 2017;16(1):30–33. doi: 10.1016/j.jccase.2017.04.003.
   PubMedGoogle Scholar
• Kalay Z, Sahin OE, Copur S, et al. SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence. Clin Kidney J. 2023;16(1):52–60. doi: 10.1093/ckj/sfac189.
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Kraus BJ, Inzucchi SE, et al. Nephrotic-range proteinuria in type 2 diabetes: effects of empagliflozin on kidney disease progression and clinical outcomes. EClinicalMedicine. 2021;43:101240. doi: 10.1016/j.eclinm.2021.101240.
   PubMedGoogle Scholar
• American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S175–S184. doi: 10.2337/dc22-S011.
   PubMedGoogle Scholar
• Zhong Y, Deng Y, Chen Y, et al. Therapeutic use of traditional Chinese herbal medications for chronic kidney diseases. Kidney Int. 2013;84(6):1108–1118. doi: 10.1038/ki.2013.276.
   PubMed Web of Science ®Google Scholar
• Liu P, Zhang J, Wang Y, et al. The Active Compounds and Therapeutic Target of Tripterygium wilfordii Hook. f. in Attenuating Proteinuria in Diabetic Nephropathy: A Review. Front Med. 2021;8:747922. doi: 10.3389/fmed.2021.747922.
   Web of Science ®Google Scholar
• Ge Y, Xie H, Li S, et al. Treatment of diabetic nephropathy with Tripterygium wilfordii Hook F extract: a prospective, randomized, controlled clinical trial. J Transl Med. 2013;11(1):134. doi: 10.1186/1479-5876-11-134.
   PubMedGoogle Scholar
• Xiong C, Li L, Bo W, et al. Evaluation of the efficacy and safety of TWHF in diabetic nephropathy patients with overt proteinuria and normal eGFR. J Formos Med Assoc. 2020;119(3):685–692. doi: 10.1016/j.jfma.2019.11.001.
   PubMed Web of Science ®Google Scholar
• Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–2045. doi: 10.2215/CJN.11491116.
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012;60(5):850–886. doi: 10.1053/j.ajkd.2012.07.005.
   PubMed Web of Science ®Google Scholar
• Stevens LA, Claybon MA, Schmid CH, et al. Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating the glomerular filtration rate in multiple ethnicities. Kidney Int. 2011;79(5):555–562. doi: 10.1038/ki.2010.462.
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869. doi: 10.1056/NEJMoa011161.
   PubMed Web of Science ®Google Scholar
• Little RJA. Testing the equality of two independent binomial proportions. The American Statistician. 1989;43(4):283–288. doi: 10.2307/2685390.
   Web of Science ®Google Scholar
• Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol. 2013;13(1):152. doi: 10.1186/1471-2288-13-152.
   PubMed Web of Science ®Google Scholar
• Neuen BL, Ohkuma T, Neal B, et al. Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. J Am Soc Nephrol. 2019;30(11):2229–2242. doi: 10.1681/ASN.2019010064.
   PubMed Web of Science ®Google Scholar
• Uno H, Claggett B, Tian L, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014;32(22):2380–2385. doi: 10.1200/JCO.2014.55.2208.
   PubMed Web of Science ®Google Scholar
• Zhou Y-Z, Zhao L-D, Chen H, et al. Comparison of the impact of Tripterygium wilfordii Hook F and Methotrexate treatment on radiological progression in active rheumatoid arthritis: 2-year follow up of a randomized, non-blinded, controlled study. Arthritis Res Ther. 2018;20(1):70. doi: 10.1186/s13075-018-1563-6.
   PubMedGoogle Scholar
• Lv Q-W, Zhang W, Shi Q, et al. Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial. Ann Rheum Dis. 2015;74(6):1078–1086. doi: 10.1136/annrheumdis-2013-204807.
   PubMed Web of Science ®Google Scholar
• Sun J, Shen X, Dong J, et al. Tripterygium wilfordii Hook F as Maintenance Treatment for Crohn’s Disease. Am J Med Sci. 2015;350(5):345–351. doi: 10.1097/MAJ.0000000000000591.
   PubMed Web of Science ®Google Scholar
• Wang Z, Yu C, Zhou L-N, et al. Effects of Tripterygium wilfordii Induction Therapy to IgA Nephropathy Patients with Heavy Proteinuria. Biol Pharm Bull. 2017;40(11):1833–1838. doi: 10.1248/bpb.b17-00134.
   PubMed Web of Science ®Google Scholar
• Liu X, Lin L, Lv T, et al. Combined multi-omics and network pharmacology approach reveals the role of Tripterygium Wilfordii Hook F in treating HIV immunological non-responders. Phytomedicine. 2022;101:154103. doi: 10.1016/j.phymed.2022.154103.
   PubMed Web of Science ®Google Scholar
• Zheng C-X, Chen Z-H, Zeng C-H, et al. Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro. Kidney Int. 2008;74(5):596–612. doi: 10.1038/ki.2008.203.
   PubMed Web of Science ®Google Scholar
• Chen Z-H, Qin W-S, Zeng C-H, et al. Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro. Kidney Int. 2010;77(11):974–988. doi: 10.1038/ki.2010.41.
   PubMed Web of Science ®Google Scholar
• Gao Q, Shen W, Qin W, et al. Treatment of db/db diabetic mice with triptolide: a novel therapy for diabetic nephropathy. Nephrol Dial Transplant. 2010;25(11):3539–3547. doi: 10.1093/ndt/gfq245.
   PubMed Web of Science ®Google Scholar
• Guo H, Pan C, Chang B, et al. Triptolide Improves Diabetic Nephropathy by Regulating Th Cell Balance and Macrophage Infiltration in Rat Models of Diabetic Nephropathy. Exp Clin Endocrinol Diabetes. 2016;124(6):389–398. doi: 10.1055/s-0042-106083.
   PubMed Web of Science ®Google Scholar
• Ma R, Liu L, Liu X, et al. Triptolide markedly attenuates albuminuria and podocyte injury in an animal model of diabetic nephropathy. Exp Ther Med. 2013;6(3):649–656. doi: 10.3892/etm.2013.1226.
   PubMed Web of Science ®Google Scholar
• Zhang M, Chen Y, Yang M-J, et al. Celastrol attenuates renal injury in diabetic rats via MAPK/NF-κB pathway. Phytother Res. 2019;33(4):1191–1198. doi: 10.1002/ptr.6314.
   PubMed Web of Science ®Google Scholar
• Han F, Wang S, Chang Y, et al. Triptolide prevents extracellular matrix accumulation in experimental diabetic kidney disease by targeting microRNA-137/Notch1 pathway. J Cell Physiol. 2018;233(3):2225–2237. doi: 10.1002/jcp.26092.
   PubMed Web of Science ®Google Scholar
• Li X-Y, Wang S-S, Han Z, et al. Triptolide Restores Autophagy to Alleviate Diabetic Renal Fibrosis through the miR-141-3p/PTEN/akt/mTOR pathway. Mol Ther Nucleic Acids. 2017;9:48–56. doi: 10.1016/j.omtn.2017.08.011.
   PubMedGoogle Scholar
• Chang B, Chen W, Zhang Y, et al. Tripterygium wilfordii mitigates hyperglycemia-induced upregulated Wnt/β-catenin expression and kidney injury in diabetic rats. Exp Ther Med. 2018;15(4):3874–3882. doi: 10.3892/etm.2018.5901.
   PubMed Web of Science ®Google Scholar
• Ru Y, Luo Y, Zhou Y, et al. Adverse Events Associated With Treatment of Tripterygium wilfordii Hook F: A Quantitative Evidence Synthesis. Front Pharmacol. 2019;10:1250. doi: 10.3389/fphar.2019.01250.
   PubMed Web of Science ®Google Scholar